Form 4: Regeneron Director Sells Shares Under 10b5-1 Plan

Regeneron Pharmaceuticals Director Arthur F. Ryan sold 100 shares of common stock on March 2, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Arthur F. Ryan, a Director of Regeneron Pharmaceuticals, Inc. (REGN), sold a total of 100 shares of common stock.
• The sales occurred on March 2, 2026, through multiple transactions.
• The shares were sold at volume-weighted average prices ranging from $777.46 to $789.28 per share.
• These dispositions were made pursuant to a Rule 10b5-1(c) trading plan adopted on October 31, 2025.
• Following these transactions, Arthur F. Ryan beneficially owns 17,703 shares of Regeneron common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were executed under a pre-established 10b5-1 plan, indicating a planned disposition rather than a reaction to new company developments.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned disposition rather than a reaction to new, non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, reduces their direct ownership stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent risk of a director reducing their stake, which is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, particularly by directors, are common occurrences and are often pre-scheduled through 10b5-1 plans to avoid accusations of trading on material non-public information. Such routine sales typically have minimal impact on broader industry trends or competitive dynamics.

Comparison to Industry Standards

• This Form 4 filing does not provide information that allows for a direct comparison to global industry benchmarks or specific comparable companies/projects, as it details a routine insider transaction.

Stakeholder Impact

• Shareholders: The sale of 100 shares by a director is a very small percentage of the company's total outstanding shares and is unlikely to have a material impact on the overall shareholder base.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The reported insider sale is a routine transaction executed under a pre-arranged 10b5-1 plan and involves a very small number of shares relative to the company's market capitalization. It does not provide new material information to warrant a change in investment recommendation, thus a 'hold' stance is maintained.

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Trading, Stock Sale, Director, Arthur F. Ryan, 10b5-1 Plan, Equity Disposition